CTEC1N Stock Chart & Stats
$59.76
$0.00(0.00%)
At close: 4:00 PM EDT
$59.76
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$59.76 - $60.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$103.56B
Enterprise Value$6.06K
Total Cash (Recent Filing)$75.03M
Total Debt (Recent Filing)$1.52B
Price to Earnings (P/E)34.7
Beta0.16
Next Earnings
Aug 04, 2026EPS Estimate
1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$69.21Price Target Upside15.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.05
Revenue Forecast (FY)$597.30M
Bulls Say, Bears Say
Bulls Say
Consistent Organic GrowthA multi-year track record of >5% organic growth in a recurring consumables business indicates durable end-market demand and pricing/reimbursement resilience. That consistency improves visibility for capacity planning and supports medium-term revenue targets and product launch ROI.
Margin Expansion And Operational LeverageSustained operating margin improvement reflects structural cost discipline, productivity and favorable product mix. Higher operating margins translate into stronger operating cash flow, greater ability to fund growth CapEx and returns, and more cushion against reimbursement or inflationary headwinds.
Strong Cash Generation And Capital AllocationConsistently positive free cash flow with high conversion supports durable capital allocation: funding growth CapEx, buybacks and dividend increases without fully relying on new equity. This cash profile underpins strategic investments and provides flexibility through economic cycles.
Bears Say
Rising Leverage Reduces FlexibilityA step‑up in leverage weakens financial flexibility and increases sensitivity to interest rates and earnings volatility. With higher debt weighting, sustained capex or adverse reimbursement shocks could force tradeoffs between investment, M&A and shareholder returns, constraining strategic optionality.
Regulatory Quality Systems Risk (FDA)Deficiencies in complaints/CAPA require remediation and sustained compliance investment. Regulatory lapses risk slower approvals, increased inspection scrutiny, product recalls or restrictions, and can delay launches—structural risks that raise operating costs and undermine growth execution.
Reimbursement Shock And Asset Impairment (InnovaMatrix)A large, policy‑driven reimbursement cut and subsequent impairment underscore exposure to payer decisions for acquired products. Such shocks can transiently depress revenue, require goodwill write‑downs, complicate integration economics and temper returns from future acquisitions in similar markets.
ConvaTec News
CTEC1N FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was $59.76 and its highest was $60.46 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is $103.56B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 4 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported $1.692 earnings per share for the quarter, missing the consensus estimate of $1.744 by -$0.052.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec does not currently pay dividends.
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 1.43.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of $1.692 in its last earnings report, missing expectations of $1.744. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in MX:CTEC1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.21 (15.81% Upside)
$69.21 (15.81% Upside)
Insider Transactions
Bought Shares
Worth $3.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.45%
12-Months-Change
Fundamentals
Return on Equity
2.27%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
CTEC1N Stock 12 Month Forecast
Average Price Target
$69.21
▲(15.81% Upside)